Taysha Gene Therapies
NASDAQ: TSHA $4.09 USD
Clinical-stage company developing AAV-based gene therapies for monogenic diseases of the central nervous system, with a lead program in Rett syndrome.
Company Info
Clinical Development Pipeline
TSHA-102
Target: MECP2Recent News
No recent news updates available for this company.
Leadership Team
Sean Nolan
Chief Executive Officer and Chairman
Kamran Alam
Chief Financial Officer
Tracy M. Porter
Chief People Officer